DMK Pharmaceuticals Profit Margin

DMK Pharmaceuticals (DMK) currently reports a profit margin of -556.72% as of December 2022. That compares with -2074.91% in the prior-year period — up 73.2% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore DMK Pharmaceuticals's profit margin history and peer comparisons.

DMK Pharmaceuticals's profit margin increased from -2074.91% to -556.72% — a 73.2% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

DMK Pharmaceuticals's profit margin of -556.72% is lower than the Healthcare sector average of 21.34%. That is roughly 2709.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but DMK Pharmaceuticals's current -556.72% should be judged against Healthcare norms (sector average: 21.34%) and against DMK's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -556.72%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for DMK Pharmaceuticals, and consider following DMK for alerts when major investors trade the stock.